These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20127368)

  • 1. Bezafibrate for the treatment of primary sclerosing cholangitis.
    Mizuno S; Hirano K; Tada M; Yamamoto K; Yashima Y; Yagioka H; Kawakubo K; Ito Y; Kogure H; Sasaki T; Arizumi T; Togawa O; Matsubara S; Nakai Y; Sasahira N; Tsujino T; Isayama H; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2010 Jul; 45(7):758-62. PubMed ID: 20127368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
    Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
    J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis.
    Kurihara T; Maeda A; Shigemoto M; Yamashita K; Kamatani N
    J Gastroenterol; 2003; 38(3):300-1. PubMed ID: 12693383
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis.
    Mizuno S; Hirano K; Isayama H; Watanabe T; Yamamoto N; Nakai Y; Sasahira N; Tada M; Omata M; Koike K
    J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):766-70. PubMed ID: 26173026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report].
    Gondoh K; Ono T; Miyakoda K; Mukasa M; So A; Imamura K; Sata M
    Nihon Shokakibyo Gakkai Zasshi; 2006 Jun; 103(6):643-9. PubMed ID: 16800287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term prognostic factors for primary sclerosing cholangitis.
    Watanabe T; Hirano K; Tada M; Isayama H; Mizuno S; Arizumi T; Toda N; Sugawara Y; Kokudo N; Koike K
    J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP).
    Fukuo Y; Kitami T; Nomoto T; Terashi A
    Nihon Ika Daigaku Zasshi; 1996 Oct; 63(5):424-30. PubMed ID: 8937134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
    Nakamuta M; Fujino T; Yada R; Yasutake K; Yoshimoto T; Harada N; Yada M; Higuchi N; Kato M; Kohjima M; Taketomi A; Maehara Y; Nishinakagawa T; Machida K; Matsunaga K; Nakashima M; Kotoh K; Enjoji M
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):22-8. PubMed ID: 20040336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
    Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
    Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
    de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
    Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel treatment for refractory primary biliary cirrhosis?
    Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
    Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
    Ohmoto K; Mitsui Y; Yamamoto S
    Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [No Abstract]   [Full Text] [Related]  

  • 18. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
    Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
    N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
    Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
    Davies YK; Cox KM; Abdullah BA; Safta A; Terry AB; Cox KL
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):61-7. PubMed ID: 18607270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.